Medical Condition News

RSS

Excessive alcohol intake may increase of cognitive dysfunction, dementia in the elderly

Alzheimer's disease (AD) and other types of dementia are most common in the very elderly, and are associated with huge health costs. With a rapidly ageing population throughout the world, factors that affect the risk of cognitive decline and dementia are of great importance. A review paper by Kim JW et al published in Psychiatry Investig 2012;9:8-16 on the association between alcohol consumption and cognition in the elderly provides an excellent summary of the potential ways in which alcohol may affect cognitive function and the risk of dementia, both adversely and favourably as alcohol may have both a neuro toxic and neuro protective effect, depending on the dose and drinking pattern.

23 May 2012

Enrollment complete in Baxano’s iO-Flex System study

Baxano, Inc., a Silicon Valley based medical device company and manufacturer of the iO-Flex System used in spinal decompression surgery, today announced it has completed enrollment in its iO-Flex Study.

23 May 2012

International task force unveils revised definition of ARDS

An international task force this week unveiled a revised definition of acute respiratory distress syndrome (ARDS), a disease first recognized during the Vietnam War in casualties with limb injuries who had trouble breathing.

23 May 2012

NIH Pain Consortium selects 11 health professional schools as CoEPEs

The National Institutes of Health Pain Consortium has selected 11 health professional schools as designated Centers of Excellence in Pain Education (CoEPEs).

23 May 2012

Critically ill patients on antidepressants more likely to die

Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly prescribed antidepressants when they were admitted to the intensive care unit (ICU).

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

“Networks” succeed in finding kidney donors: John Hopkins program reports

Johns Hopkins researchers say a program they developed that uses personal advocates and community networks to find organ donors for friends and loved ones who need kidney transplants resulted in success for nearly half of the participants in its trial run.

22 May 2012

Pop rock concert may lead to hearing loss among teenagers

Seventy-two percent of teenagers participating in a study experienced reduced hearing ability following exposure to a pop rock performance by a popular female singer.

22 May 2012

Combination therapy does not reduce mortality rates associated with severe sepsis

Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on sepsis-related organ dysfunction.

22 May 2012

New evidence behind WOUNDCHEK Protease Status to be presented at EWMA conference

New evidence behind the world's first point of care wound diagnostic test, WOUNDCHEK Protease Status, to be presented at the European Wound Management Association (EWMA)'s conference in May 2012 confirms the importance of protease activity in wound healing and wound assessment, quantifies elevated protease activity (EPA), and also presents preliminary results on testing for and treating EPA in clinical practice.

22 May 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

GE Healthcare, KUH partner to drive advances in cell therapy technologies

Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

22 May 2012

Inexpensive sleep disorder drug appears to be potent inhibitor of cancer cells

An inexpensive "orphan drug" used to treat sleep disorders appears to be a potent inhibitor of cancer cells, according to a new study led by scientists at Fred Hutchinson Cancer Research Center.

22 May 2012

Studies of technological innovations presented at DDW annual meeting

Studies of technological innovations being presented for the first time at Digestive Disease Week- (DDW) showed increased accuracy coupled with decreased cost, time or invasiveness of gastrointestinal procedures. Use of a new high-definition colonoscope, for example, improved physician confidence in diagnosing small polyps, potentially reducing the amount of polyps sent for pathology analysis and the associated costs.

From Evident Corporation - Life Sciences 22 May 2012

Statins may reduce hospital stay for patients with stroke

A new study suggests that using cholesterol-lowering medications known as statins after having a stroke may increase the likelihood of returning home and lessen the chance of dying in the hospital.

22 May 2012

New definition for acute respiratory distress syndrome

Gordon D. Rubenfeld, M.D., of the Sunnybrook Health Sciences Center, Toronto, Canada, and colleagues with the ARDS (acute respiratory distress syndrome) Definition Task Force, developed a new definition of ARDS (the Berlin Definition) that focused on feasibility, reliability, validity and objective evaluation of its performance.

22 May 2012

$Bisphosphonate therapy may increase risk of atypical femoral fractures$

Bisphosphonate therapy may increase risk of atypical femoral fractures

Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

22 May 2012

Researchers to create new type of bioactive coating for brain aneurysm stents

Researchers at Purdue University are working with the U.S. Army and neurosurgeons at the Walter Reed National Military Medical Center to create a new type of "bioactive" coating for stents used to treat brain aneurysms including those caused by head trauma from bomb blasts.

22 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

Viewpoints: A gamble on Alzheimer's research; Hidden costs of insurance rebates

The Obama administration has announced a bold research program to test whether a drug can prevent the onset of Alzheimer's disease well before any symptoms appear. It is a long shot, but the payoff could be huge.

22 May 2012